TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04698512

Intervention type: DEVICE
Intervention: AVFistuloplasty with Sirolimus coated balloon
Description: After an initial fistulogram, the lesion will first be predicated with standard high pressure balloon, followed by MagicTouch™ Sirolimus drug coated balloon
Study: NCT01477138

Intervention type: PROCEDURE
Intervention: pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)
Description: Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.

Intervention type: PROCEDURE
Intervention: pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)
Description: Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
Study: NCT05735613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteotome crestal sinus lifting
Description: Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. The drills can be sequentially used to widen the osteotomy site to the same level (1 mm short of the sinus floor), an osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level, the osteotome will be tapped gently to fracture up the sinus floor.Clinical check for membrane still intact, blocking the patient's nostrils and asking the patient to blow through his or her nose. Xenograft will be added as the grafting material and pushed to the sinus through the osteotomy site until the desired height of sinus elevation will be gained, the implant fixture will be inserted. Smart peg will be placed on implant and Ostell will be used to record ISQ.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseodensification crestal sinus lifting
Description: Full thickness flap elevated to expose the crest of alveolar ridge. Pilot drill used to start the osteotomy preparation, which should be ended 1mm short of sinus floor. Change the drill motor to reverse-densifying Mode (counterclockwise drill speed 800-1500 rpm with copious irrigation), Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor, use the next wider Densah Bur (3.0mm) in the same mode and advance it into the previously created osteotomy with modulating pressure and a pumping motion. When feeling the haptic feedback of the drill reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments, the next wider densah drills advance in the osteotomy.Clinical check for membrane still intact. Xenograft added and pushed to the sinus through the osteotomy site then the implant fixture will be inserted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezoelectric crestal sinus lifting
Description: initial osteotomy will be performed with a 2-mm twist drill to remove the cortical bone, then the intralift tips (Intralift; TKW1, TKW2, TKW3,TKW4, TKW5; Satelec). TKW1 to TKW4 tips have diameters of 1.35 mm, 2.1 mm, 2.35 mm, and 2.8 mm and will be used to gradually widen the access canal to the Schneider membrane, gentle pressure will be applied on the tips to deepen the pathway, and a sterile spray (80 mL/min) cooling the tips to avoid heat injury. The TKW5 tip will be then inserted into the access canal, and the ultrasonic activation for 5 seconds with internal irrigation of 40 mL/min and repeated at 50 mL/min and then 60 mL/min. The sinus membrane will be pushed upward by the hydraulic pressure, the floating of the sinus membrane will be evaluated, and then the TKW4 (Ø 2.8 mm) will be used again to widen the access canal to the sinus membrane before plugging the bone graft.xenograft added. Implant fixture inserted and flap statured
Study: NCT04559087

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic Surgery
Description: NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: NOSES:Natural orifice specimen extraction (NOSE) is the opening of a hollow viscus that already communicates with the outside world, such as the vagina or distal gastrointestinal tract, in order to remove a specimen. The premise of this technique is to reduce the trauma required to remove the specimen with the expectation that this may improve outcomes.~Conventional Laparoscopic Surgery:Surgical specimens were taken out through abdominal wall.
Study: NCT03443895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEF0117 oral capsule
Description: 0.6, 2 and 6mg of AEF0117
Study: NCT01309932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (NS5A Inhibitor)
Description: Tablets, Oral, 60 mg, Once daily, 24 weeks
Study: NCT04858113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blephaclean
Description: Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Baby Shampoo
Description: Conventional baby shampoo
Study: NCT01309932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (NS5A Inhibitor)
Description: Tablets, Oral, 60 mg, Once daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (NS5A Inhibitor)
Description: Tablets, Oral, 60 mg, Once daily, 24 weeks
Study: NCT04570306

Intervention type: DRUG
Intervention: Belimumab
Description: The study will involve 80 adult patients diagnosed with SLE who will be started on belimumab (standard approved dose of i.v. 10 mg/kg or subcutaneous 200 mg/week) due to active disease. The intention to start belimumab will be made by the treating Rheumatologist(s), in accordance to the current standard of care, and on the basis of shared physician-patient decision making.
Study: NCT00119197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: killed whole cell oral cholera vaccine
Description: Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~* Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~* Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~* Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~* Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Heat Killed E. coli
Description: Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart
Study: NCT03067402

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nuclear Perfusion Imaging Stress Test
Description: Patient receives routine nuclear image perfusion stress test
Study: NCT01109186

Intervention type: OTHER
Intervention: biological parameters
Description: blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
Study: NCT00836394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galileo (whole body vibration (WBV) therapy)
Description: 6 minutes of training on 5 days a week for 3 months
Study: NCT00412191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
Study: NCT03011749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FLT PET/CT
Description: FLT PET/CT before first series of Radium-223 and after 2 series
Study: NCT03443895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsule
Study: NCT00367432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
Study: NCT01376362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Gamma-1b
Description: Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
Study: NCT03723980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
Study: NCT03228862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 40000, 60000 and 80000 once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 40000, 60000 and 80000 once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 40000, 60000 and 80000 once weekly
Study: NCT00347932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-403
Description: Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
Study: NCT01724216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse sequences
Description: Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
Study: NCT00504439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933-AAA
Description: The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
Study: NCT02407912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: ciplatin in distilled water is injected into the chest for 48 h.
Study: NCT03351478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 400 mg was administered as two tablets, once daily before the first meal of the day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Empagliflozin 25 mg capsule was administered, once daily before the first meal of the day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as two tablets (identical to sotagliflozin in appearance), once daily before the first meal of the day.
Study: NCT00504439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933-AAA
Description: The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-656933-AAA
Description: The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
Study: NCT03351478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered as one capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day.
Study: NCT02581124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study: NCT00471003

Intervention type: DRUG
Intervention: Pritor (Telmisartan , BAY68-9291)
Description: Primary care hypertensive patients starting the therapy with Telmisartan
Study: NCT01291849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dixon up-and-down method
Description: The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
Study: NCT02969538

Intervention type: OTHER
Group type: OTHER
Intervention: Total etching time
Description: Apply 35% phosphoric acid on dentin and enamel by 15 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half-reduced etching time
Description: Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
Study: NCT01001364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol/Budesonide
Description: formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foraseq
Description: formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
Study: NCT00504439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: SB-656933-AAA matching placebo tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: SB-656933-AAA matching placebo tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: SB-656933-AAA matching placebo tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin will be provided as a 40 mg tablet.
Study: NCT03755999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The premature infant oral motor intervention (PIOMI)
Description: The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
Study: NCT01059006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PresbyLASIK
Description: PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
Study: NCT03151122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led Continuous Support
Description: The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine follow-up care
Description: after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
Study: NCT00524888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suturing laceration
Description: suturing simple lacerations of the hand

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bioadhesive
Description: using bioadhesive on simple lacerations of the hand
Study: NCT03112291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apexification
Description: Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
Study: NCT00335309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary Sinus Irrigation
Description: Twice a day irrigation with 100cc saline for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Amoxicillin and Clavulanate acid
Description: IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
Study: NCT02638714

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: Intervention: Transplantation of autologous purified stem cells
Study: NCT00830804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400 mg tablet taken orally twice daily
Study: NCT01312727

Intervention type: OTHER
Group type: OTHER
Intervention: Blood and urine sample collections
Description: phenotype and genotype analysis, biological analysis
Study: NCT01719848

Intervention type: OTHER
Intervention: Measurements of parameters related with physical examinations for difficult airway prediction
Study: NCT04298294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin
Description: biologic activator
Study: NCT04845594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MySmileBuddy (MSB)
Description: The technology-based MSB program equips community health workers (CHWs) with an iPad-based app that facilitates assessment of a child's early childhood caries (ECC).
Study: NCT00560092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal magnesium sulfate
Description: intrathecal magnesium sulfate
Study: NCT00413660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 4 blinded tablets administered BID
Study: NCT00830804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir
Description: 800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
Study: NCT02907086

Intervention type: OTHER
Intervention: blood collection
Description: Patients will receive a research draw for circulating tumor material analysis with standard clinical labs

Intervention type: OTHER
Intervention: blood collection
Description: Patients will receive a research draw for circulating tumor material analysis with standard clinical labs
Study: NCT00413660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 4 blinded tablets administered BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 4 blinded tablets administered BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 4 blinded tablets administered BID
Study: NCT01035008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound (EUS)
Description: The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
Study: NCT01809678

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Once weekly program of cognitive-behavioral therapy for smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Once weekly program of cognitive-behavioral therapy for smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Twice weekly program of 1-hour Iyengar yoga classes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: Twice weekly program of 1-hour wellness classes on a variety of health topics.
Study: NCT00686010

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, 3 tablets, oral, once daily after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 300mg
Description: JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 600mg
Description: JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-705 900mg
Description: JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
Study: NCT03515213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 145mg of fenofibrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo